Jiangsu / Biomedicine Company Structure Study

Comparative structure study

The largest recorded chain role, Biomedicine and medical devices / Complete systems and use-case applications, contains 185 records (75.2% of this 246-record cohort). Companies may carry multiple labels in this dimension; participation rates are not additive market shares.

The recorded sub-industry label Advanced medical devices accounts for 45.5% here (112/246), compared with 35.4% in the parent set (609/1,721), an absolute gap of 10.1 percentage points.

157/246 companies link to pages with existing source-supported excerpts (63.8% of the cohort). The other 89 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine, contains 1,721 records. This cohort contributes 246 (14.3%); 1,475 records remain after excluding it.

The parent set, Jiangsu, contains 3,025 records. This cohort contributes 246 (8.1%); 2,779 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded sub-industry label Advanced medical devices covers 497/1,475 remaining records (33.7%), an absolute gap of 11.8 percentage points from this cohort.

The table shows ten labels; 4 others are included in the calculations above.

Record counts do not rank supply capability or economic size.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

47 of this cohort’s 246 records link through existing company-ID mappings to 2026 lists from all jurisdictions (19.1%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

The 2025 macro context for Jiangsu uses a different denominator from this cohort.

Drug-production leads need validation and change records

The Chemical drugs and formulations label covers 18 records (7.3% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.

Shared records with Jiangsu / Biomedicine and medical devices / Complete systems and use-case applications Company Structure Study: 185; records in this cohort but outside that set: 61. The intersection/union ratio is 72.0%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine / Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 185; records in this cohort but outside that set: 61. The intersection/union ratio is 13.7%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.